Posted by Michael Wonder on 29 Jan 2024
Enhertu granted priority review in the US for patients with metastatic HER2 positive solid tumours
29 January 2024 - Application based on results from DESTINY-PanTumor02 trial and supported by additional Enhertu data.
Daiichi Sankyo and AstraZeneca's supplemental biologics license application for Enhertu (famtrastuzumab deruxtecan-nxki) has been accepted and granted priority review in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry 3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options.
